AlpInvest Partners B.V. cut its holdings in shares of Fate Therapeutics Inc (NASDAQ:FATE) by 21.6% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 21,104 shares of the biopharmaceutical company’s stock after selling 5,821 shares during the period. Fate Therapeutics accounts for 0.5% of AlpInvest Partners B.V.’s portfolio, making the stock its 22nd biggest position. AlpInvest Partners B.V.’s holdings in Fate Therapeutics were worth $371,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also bought and sold shares of FATE. Vanguard Group Inc. lifted its holdings in shares of Fate Therapeutics by 12.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,448,279 shares of the biopharmaceutical company’s stock valued at $39,882,000 after buying an additional 275,828 shares during the period. Alps Advisors Inc. lifted its stake in shares of Fate Therapeutics by 57.7% in the 4th quarter. Alps Advisors Inc. now owns 149,103 shares of the biopharmaceutical company’s stock worth $1,913,000 after acquiring an additional 54,571 shares during the period. State Board of Administration of Florida Retirement System lifted its stake in shares of Fate Therapeutics by 19.1% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 21,601 shares of the biopharmaceutical company’s stock worth $277,000 after acquiring an additional 3,462 shares during the period. Creative Planning acquired a new stake in shares of Fate Therapeutics in the 4th quarter worth approximately $141,000. Finally, Victory Capital Management Inc. lifted its stake in shares of Fate Therapeutics by 150.1% in the 4th quarter. Victory Capital Management Inc. now owns 1,318,860 shares of the biopharmaceutical company’s stock worth $16,921,000 after acquiring an additional 791,540 shares during the period. 93.28% of the stock is currently owned by hedge funds and other institutional investors.
In other Fate Therapeutics news, CEO J Scott Wolchko sold 8,541 shares of the business’s stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $16.17, for a total transaction of $138,107.97. Following the completion of the sale, the chief executive officer now directly owns 375,973 shares in the company, valued at approximately $6,079,483.41. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Daniel D. Shoemaker sold 12,500 shares of the business’s stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $20.21, for a total value of $252,625.00. Following the sale, the insider now owns 148,091 shares of the company’s stock, valued at $2,992,919.11. The disclosure for this sale can be found here. In the last 90 days, insiders sold 35,376 shares of company stock valued at $668,402. 23.19% of the stock is owned by company insiders.
Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.07). Fate Therapeutics had a negative net margin of 1,138.12% and a negative return on equity of 54.30%. The company had revenue of $2.63 million during the quarter, compared to analyst estimates of $2.01 million. During the same period last year, the firm earned ($0.27) EPS. The business’s quarterly revenue was up 156.3% compared to the same quarter last year. As a group, equities analysts predict that Fate Therapeutics Inc will post -1.29 EPS for the current year.
Several research analysts have recently commented on the stock. BidaskClub upgraded shares of Fate Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, May 17th. Mizuho began coverage on Fate Therapeutics in a research note on Wednesday, June 12th. They issued a “buy” rating and a $27.00 price objective for the company. Roth Capital began coverage on Fate Therapeutics in a research note on Friday, June 7th. They issued a “neutral” rating and a $20.00 price objective for the company. Wells Fargo & Co raised their price objective on Fate Therapeutics from $18.00 to $24.00 and gave the company an “outperform” rating in a research note on Wednesday, March 6th. Finally, Guggenheim initiated coverage on Fate Therapeutics in a report on Thursday, May 30th. They issued a “buy” rating and a $25.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $22.00.
Fate Therapeutics Profile
Fate Therapeutics, Inc operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system.
Featured Story: Dividend Aristocrat Index
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.